Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study
about
Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [ISRCTN25438351]Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondyloarthritis) and gastrointestinal or liver comorbidityPain management for rheumatoid arthritis and cardiovascular or renal comorbidityNew horizons and perspectives in the treatment of osteoarthritisNSAID-induced antral ulcers are associated with distinct changes in mucosal gene expression.Naproxen aggravates doxorubicin-induced cardiomyopathy in rats.Predictors of pain medication use for arthroplasty pain after revision total knee arthroplastyIndividual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project)Persistent nonmalignant pain management using nonsteroidal anti-inflammatory drugs in older patients and use of inappropriate adjuvant medications.Recognizing the Risks of Chronic Nonsteroidal Anti-Inflammatory Drug Use in Older Adults.Comparison of analgesic efficacy of flupirtine maleate and ibuprofen in gynaecological ambulatory surgeries: A randomized controlled trial.Pain management for dentists: the role of ibuprofen.Adverse effects of analgesics commonly used by older adults with osteoarthritis: focus on non-opioid and opioid analgesicsProphylaxis of heterotopic ossification - an updated review.The search for new COX-2 inhibitors: a review of 2002 - 2008 patents.Celecoxib in arthritis: relative risk management profile and implications for patients.Defining a reference set to support methodological research in drug safety.Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC.Celecoxib for the treatment of atherosclerosis.Discrepancy among observational studies: example of naproxen-associated adverse eventsShould acetaminophen be added to the list of anti-inflammatory agents that are associated with cardiovascular events?Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population.Nanohybridization of Low-Dimensional Nanomaterials: Synthesis, Classification, and Application
P2860
Q21254655-5A4F2FDF-266C-4083-92D1-04466D84C8ECQ24203871-463F7DB2-1CE0-4B0D-AA13-C32152EED89EQ24235971-FD5E7451-4E41-400D-BF70-7459BDB14715Q24657795-FB60B170-F06E-441D-BC6B-283CEA54E262Q33701847-602C8D54-D6BC-4271-8239-A0BDE59585A8Q33913113-01D6D795-0A08-4893-8794-D752A1C33EB1Q34195997-3C9E3592-BF15-46AC-BD1E-C8BDE2B74B80Q34310573-580CC95B-A5D5-4435-B311-5FF3CEC6E64BQ35057487-618AAA74-7E46-4E2E-8554-65E42A0719FBQ35171694-9CDCED70-385B-49B5-ABB7-2F4AAE1367A6Q35913624-913692B5-F164-4606-B79A-0ABBE991D433Q36148700-1423E0D3-8B0E-4972-A363-A591B75C3D76Q36485541-6081F793-D8E3-4700-97B6-2C5930E26E8EQ37451829-BED52C3A-B4E5-4E3F-B3CC-EE1B21528A79Q37534725-6982C0DB-EB6D-48E9-971A-06801A651DC1Q37643458-B4A9B0BA-6A1D-4FC1-AF20-037ED0E57708Q38156066-57177C68-A98D-4430-AB93-A0B13DAB13D8Q38164425-0A632FCE-6C83-449F-8B0A-43A1F7773C7BQ38759585-7E91E38D-A7C1-458E-BA6D-52B4C5364586Q41511728-C39090C7-179E-47EB-AD99-DE68FC4D574CQ42585153-B1615E6F-DCDE-444E-A365-D8EFEA6F23E5Q44640097-C163812E-7CE7-469B-B121-763AC05606AEQ57370700-690B967C-89E0-4394-80F8-3123C98B2755
P2860
Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Risks and benefits of COX-2 in ...... ? A retrospective cohort study
@ast
Risks and benefits of COX-2 in ...... ? A retrospective cohort study
@en
Risks and benefits of COX-2 in ...... ? A retrospective cohort study
@nl
type
label
Risks and benefits of COX-2 in ...... ? A retrospective cohort study
@ast
Risks and benefits of COX-2 in ...... ? A retrospective cohort study
@en
Risks and benefits of COX-2 in ...... ? A retrospective cohort study
@nl
prefLabel
Risks and benefits of COX-2 in ...... ? A retrospective cohort study
@ast
Risks and benefits of COX-2 in ...... ? A retrospective cohort study
@en
Risks and benefits of COX-2 in ...... ? A retrospective cohort study
@nl
P356
P1433
P1476
Risks and benefits of COX-2 in ...... ? A retrospective cohort study
@en
P2093
P356
10.1093/RHEUMATOLOGY/KEL428
P407
P577
2007-03-01T00:00:00Z